Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC). Impact of activating androgen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results